Bio-Techne Corporation

NasdaqGS:TECH Voorraadrapport

Marktkapitalisatie: US$11.3b

Bio-Techne Beheer

Beheer criteriumcontroles 2/4

De CEO Bio-Techne is Kim Kelderman, benoemd in Feb2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.85M, bestaande uit 11.1% salaris en 88.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.025% van de aandelen van het bedrijf, ter waarde $ 2.78M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 7.8 jaar.

Belangrijke informatie

Kim Kelderman

Algemeen directeur

US$6.9m

Totale compensatie

Percentage CEO-salaris11.1%
Dienstverband CEOless than a year
Eigendom CEO0.02%
Management gemiddelde ambtstermijn1.3yrs
Gemiddelde ambtstermijn bestuur7.8yrs

Recente managementupdates

Recent updates

There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Nov 06
There May Be Reason For Hope In Bio-Techne's (NASDAQ:TECH) Disappointing Earnings

Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Sep 26
Is Bio-Techne (NASDAQ:TECH) A Risky Investment?

Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Sep 11
Why Bio-Techne Corporation (NASDAQ:TECH) Could Be Worth Watching

Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

Aug 24
Bio-Techne Corporation's (NASDAQ:TECH) Price In Tune With Earnings

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jun 09
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

May 21
Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up

These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Apr 30
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well

Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Apr 15
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate

Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence

Apr 04

We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Jan 17
We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt

Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Dec 30
Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Dec 05
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Oct 10
Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Sep 22
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Sep 01
A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Jul 10
At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Jun 22
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Jun 07
With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case

Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

May 23
Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Apr 05
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Mar 21
Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet

Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

Mar 06
Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching

When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

Jan 03
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?

We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Dec 15
We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease

Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Nov 30
Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?

Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Nov 17
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)

Bio-Techne releases new AVV viral titer assays

Oct 11

At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Sep 26
At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?

Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Sep 12
Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?

Bio-Techne to seek shareholder approval for 4- for-1 stock split

Sep 01

Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Aug 29
Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?

Analyse CEO-vergoeding

Hoe is Kim Kelderman's beloning veranderd ten opzichte van Bio-Techne's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

US$151m

Jun 30 2024US$7mUS$760k

US$168m

Mar 31 2024n/an/a

US$203m

Dec 31 2023n/an/a

US$224m

Sep 30 2023n/an/a

US$247m

Jun 30 2023US$3mUS$590k

US$285m

Mar 31 2023n/an/a

US$271m

Dec 31 2022n/an/a

US$262m

Sep 30 2022n/an/a

US$292m

Jun 30 2022US$3mUS$562k

US$272m

Mar 31 2022n/an/a

US$225m

Dec 31 2021n/an/a

US$210m

Sep 30 2021n/an/a

US$177m

Jun 30 2021US$4mUS$530k

US$140m

Mar 31 2021n/an/a

US$184m

Dec 31 2020n/an/a

US$175m

Sep 30 2020n/an/a

US$248m

Jun 30 2020US$2mUS$500k

US$229m

Mar 31 2020n/an/a

US$187m

Dec 31 2019n/an/a

US$195m

Sep 30 2019n/an/a

US$93m

Jun 30 2019US$2mUS$452k

US$96m

Mar 31 2019n/an/a

US$121m

Dec 31 2018n/an/a

US$96m

Sep 30 2018n/an/a

US$128m

Jun 30 2018US$2mUS$73k

US$126m

Compensatie versus markt: De totale vergoeding ($USD 6.85M ) Kim } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.67M ).

Compensatie versus inkomsten: De beloning van Kim is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.


CEO

Kim Kelderman (57 yo)

less than a year

Tenure

US$6,852,495

Compensatie

Mr. Kim Kelderman serves as Director of SLMP, LLC since November 2021. He serves as President of the Diagnostics and Genomics Segment at Bio-Techne. He served as Chief operating Officer at Bio-Techne Corpo...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Kim Kelderman
CEO, President & Directorless than a yearUS$6.85m0.025%
$ 2.8m
James Hippel
Executive VP of Finance & CFO10.6yrsUS$5.20m0.067%
$ 7.6m
Shane Bohnen
Senior VP1.7yrsUS$1.46m0.0011%
$ 120.1k
William Geist
President of Protein Sciences Segment2.8yrsUS$3.65m0.0070%
$ 789.4k
Matthew McManus
President of Diagnostics & Genomicsless than a yearUS$2.27mgeen gegevens
Gary Latham
VP & CTOless than a yeargeen gegevensgeen gegevens
David Clair
Senior Director of Investor Relations & Corporate Developmentno datageen gegevensgeen gegevens
Gerry Andros
Vice President of Sales and Marketingno datageen gegevensgeen gegevens
Martin Wirtz
Senior Vice President of Strategy & Corporate Developmentless than a yeargeen gegevensgeen gegevens
Cheryl Bethune
Senior VP & Chief Human Resources Officerless than a yeargeen gegevensgeen gegevens
Luca Cicchetti
Managing Director8.3yrsgeen gegevensgeen gegevens
Steve Crouse
Senior Vice President of Analytical Solutions Division1.8yrsgeen gegevensgeen gegevens

1.3yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TECH wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Kim Kelderman
CEO, President & Director1.8yrsUS$6.85m0.025%
$ 2.8m
Robert Baumgartner
Independent Chairman of the Board21.8yrsUS$410.46k0.028%
$ 3.2m
John Higgins
Independent Director15.5yrsUS$300.46k0.030%
$ 3.4m
Joseph Keegan
Independent Director7.8yrsUS$275.46k0.0087%
$ 981.9k
Roeland Nusse
Independent Director14.5yrsUS$290.46k0.028%
$ 3.2m
Julie Bushman
Independent Director4.3yrsUS$291.50k0.0045%
$ 508.5k
John Denu
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Sachdev Sidhu
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
S. J. Vessey
Independent Director5.4yrsUS$275.46k0.0059%
$ 666.0k
Alpna Seth
Independent Director7.8yrsUS$275.46k0.0087%
$ 981.9k
David Artis
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Judith Klimovsky
Independent Directorless than a yearUS$113.73k0.0014%
$ 152.9k

7.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TECH wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).